Company developing innovative two-fold technology designed to both detect the neural signals relating to pain or disease and ablate them in one simple procedure.
Ongoing progress toward launch of first-in-human clinical trial for the treatment of pancreatic cancer pain and pancreatitis pain in 2024.
THE WOODLANDS, TX — November 8, 2023 – Autonomix Medical, Inc. (“Autonomix” or the “Company”) a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced the launch of its new corporate social media channels. To stay up to date with Autonomix’s latest news and events, connect with the Company on Twitter, LinkedIn and Facebook.
“We believe Autonomix represents an exciting opportunity to potentially revolutionize how diseases involving the nervous system are diagnosed and treated. We continue to make significant progress toward our first-in-human clinical trial and are committed to being transparent with all of our stakeholders as we continue to advance the development of our innovative technologies. We invite you to connect with us on our social media channels as we work to establish a presence across the investment, patient and industry partner communities and provide a much-needed solution for navigating the nervous system to provide real-time precision-guided therapy across a number of high-value indications,” commented Lori Bisson, Chief Executive Officer of Autonomix.
Leveraging its catheter-based sensing technology, Autonomix is developing the ability to do two things at once: sense neural signals associated with pain or disease and destroy those nerves at the source. Until now, no clinically available technology has been sensitive enough to locally detect the electrical signals used by the bulk of our peripheral nervous system. Autonomix is designing technology to detect these faint signals, paving the way for targeted treatment not yet available in the market today. The Autonomix technology uses a proprietary microchip and unique antenna sensing array designed to enable precise targeting of treatments through a simple and safe transvascular procedure.
Ultimately, the Autonomix technology may be used to potentially treat a large number of diseases relating to nervous system function. The Company is initially focusing its efforts on helping pancreatic cancer patients and people with pancreatitis who are suffering from pain that is not relieved by currently available methods. The Company is currently working toward its proof-of-concept first-in-human clinical trial for the treatment of pancreatic cancer pain, expected to commence in 2024.
About Autonomix Medical, Inc.
Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class technology platform includes a catheter-based microchip sensing array that has the ability to detect and differentiate neural signals with approximately 3,000 times greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.
We are initially developing our technology for pancreatic cancer pain and pancreatitis pain, conditions that can cause debilitating pain and need an effective solution. However, our technology constitutes a platform with the potential to address dozens of indications, including in cardiology, renal denervation and chronic pain management across a wide disease spectrum.
For more information, visit autonomix.com and connect with the Company on Twitter, LinkedIn and Facebook.
Forward Looking Statements
Some of the statements in this release are “forward-looking statements,” which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the ability of Autonomix to successfully develop its technology platform on a timely basis. Such forward-looking statements can be identified by the use of words such as ‘’should,‘’ ‘’may,‘’ ‘’intends,‘’ ‘’anticipates,‘’ ‘’believes,‘’ ‘’estimates,‘’ ‘’projects,‘’ ‘’forecasts,‘’ ‘’expects,‘’ ‘’plans,‘’ and ‘’proposes.‘’
Although Autonomix Medical, Inc. (or Autonomix) believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading “Risk Factors” and elsewhere in the offering statement filed with the SEC. Forward-looking statements speak only as of the date of the document in which they are contained, and Autonomix does not undertake any duty to update any forward-looking statements except as may be required by law.
The offering will be made only by means of an offering circular. An offering statement on Form 1-A relating to these securities has been filed with the U.S. Securities and Exchange Commission and has become qualified. The securities offered by Autonomix are highly speculative. Investing in shares of Autonomix involves significant risks. The investment is suitable only for persons who can afford to lose their entire investment. Furthermore, investors must understand that such investment could be illiquid for an indefinite period of time. No public market currently exists for the securities, and if a public market develops following the offering, it may not continue.
Autonomix intends to list its securities on a national exchange and doing so entails significant ongoing corporate obligations including but not limited to disclosure, filing and notification requirements, as well compliance with applicable continued quantitative and qualitative listing standards. For additional information on Autonomix, the offering and any other related topics, please review the registration statement that can be found at the following location EDGAR Entity Landing Page (sec.gov). Additional information concerning Risk Factors related to the offering, including those related to the business, government regulations, intellectual property and the offering in general, can be found in the risk factor section of the Form 1-A offering circular.
Investor Relations Contact
JTC Team, LLC
Jenene Thomas
833-475-8247